首页> 外文期刊>Molecular cancer therapeutics >Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance
【24h】

Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance

机译:鞘氨氨酸-1-磷酸盐受体-1促进环境介导和获得的化学化学率

获取原文
获取原文并翻译 | 示例
           

摘要

Drug resistance is a major barrier for the development of effective and durable cancer therapies. Overcoming this challenge requires further defining the cellular and molecular mechanisms underlying drug resistance, both acquired and environment-mediated drug resistance (EMDR). Here, using neuroblastoma (NB), a childhood cancer with high incidence of recurrence due to resistance to chemotherapy, as a model we show that human bone marrow–mesenchymal stromal cells induce tumor expression of sphingosine-1-phosphate receptor-1 (S1PR1), leading to their resistance to chemotherapy. Targeting S1PR1 by shRNA markedly enhances etoposide-induced apoptosis in NB cells and abrogates EMDR, while overexpression of S1PR1 significantly protects NB cells from multidrug-induced apoptosis via activating JAK–STAT3 signaling. Elevated S1PR1 expression and STAT3 activation are also observed in human NB cells with acquired resistance to etoposide. We show in vitro and in human NB xenograft models that treatment with FTY720, an FDA-approved drug and antagonist of S1PR1, dramatically sensitizes drug-resistant cells to etoposide. In summary, we identify S1PR1 as a critical target for reducing both EMDR and acquired chemoresistance in NB. Mol Cancer Ther; 16(11); 2516–27. ?2017 AACR .
机译:耐药性是发展有效和耐用的癌症疗法的主要障碍。克服这一挑战需要进一步定义耐药性和环境介导的耐药性(EMDR)的耐药性和分子机制。在这里,使用神经母细胞瘤(Nb),一种儿童癌,由于耐化疗而具有高发次发生率的儿童癌,作为化疗的型号,我们表明人骨髓间充质基质细胞诱导胰腺炎-1-磷酸酯受体-1的肿瘤表达(S1PR1) ,导致他们对化疗的抵抗力。通过ShRNA靶向S1PR1显着增强了在Nb细胞中的依托皂苷诱导的细胞凋亡,而aqurogates emdr,而S1Pr1的过度表达通过激活Jak-Stat3信号传导显着保护来自多药诱导的细胞凋亡的Nb细胞。在具有获得依托泊苷的抗性的人Nb细胞中也观察到升高的S1PR1表达和STAT3活化。我们在体外和人NB异种移植模型中显示,用FTY720治疗FDA批准的S1PR1的药物和拮抗剂,显着敏感耐药细胞至依托泊苷。总之,我们将S1PR1识别为减少EMDR的关键目标,并在NB中获取化学抑制。 mol癌症; 16(11); 2516-27。 ?2017年AACR。

著录项

  • 来源
    《Molecular cancer therapeutics》 |2017年第11期|共12页
  • 作者单位

    Department of Immuno-Oncology Beckman Research Institute City of Hope Comprehensive Cancer Center;

    Department of Immuno-Oncology Beckman Research Institute City of Hope Comprehensive Cancer Center;

    Department of Immuno-Oncology Beckman Research Institute City of Hope Comprehensive Cancer Center;

    Department of Immuno-Oncology Beckman Research Institute City of Hope Comprehensive Cancer Center;

    Department of Immuno-Oncology Beckman Research Institute City of Hope Comprehensive Cancer Center;

    Department of Diabetes Complications and Metabolism Beckman Research Institute City of Hope;

    Division of Hematology Oncology and Blood and Bone Marrow Transplantation Department of;

    Division of Hematology Oncology and Blood and Bone Marrow Transplantation Department of;

    Department of Immuno-Oncology Beckman Research Institute City of Hope Comprehensive Cancer Center;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号